Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 9/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932874 | 0.87 | MAPT (0.61) | LMNAMAPTPGRCASP3MAOB | |
| SCHEMBL18358720 | 0.80 | PSMB8 (0.58) | PGRL3MBTL1 | |
| SCHEMBL16883632 | 0.80 | CYP1A2 (0.55) | LMNAMAPTPGRMAOB | |
| SCHEMBL20079379 | 0.80 | PGR (0.65) | PGRMAOB | |
| SCHEMBL7220155 | 0.75 | DAO (0.66) | LMNAMAPTPGRMAOBNOS1 | |
| SCHEMBL2522765 | 0.75 | LMNA (0.58) | LMNAMAPTPGRMAOB | |
| SCHEMBL29859942 | 0.75 | LMNA (0.58) | LMNAMAPTPGRMAOB | |
| SCHEMBL20338373 | 0.75 | PGR (0.60) | PGR | |
| SCHEMBL628219 | 0.75 | PGR (0.54) | LMNAMAPTPGRMAOB | |
| SCHEMBL5794772 | 0.74 | POLB (0.47) | LMNAMAPTPGRMAOBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001983-A1 | TRPA1 MODULATORS | ALGOMEDIX, INC. | 2017-01-05 | — | — | US | disclosed |
| WO-2015103060-A1 | TRPA1 MODULATORS | ALGOMEDIX, INC. (US) | 2015-07-09 | — | — | WO | disclosed |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | disclosed |
| EP-1993536-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070249599-A1 | Novel Chemical Compounds | DUFFY KEVIN J | 2007-10-25 | — | — | US | disclosed |
| WO-2007103755-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| EP-1718642-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082901-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249599-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | LMNA 1240/4885MAPT 1769/4885PGR 4800/4885 |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | LMNA 4788/4885MAPT 2228/4885PGR 929/4885 |
| US-20170001983-A1 | TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | LMNA 3839/4885MAPT 996/4885PGR 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.